At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Prescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

FTC’s report focused on three largest PBMs ... A transformation in the PBM space will likely lead to fairer pricing and improved access to essential medications for customers, ultimately ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The FTC reports that from 2017 to 2022 the three largest ... by then providing the drug to patients without the rebate the PBM can pocket the difference through spread pricing.